AMEI's Current Trends in Diagnosis & Treatment

Register      Login

VOLUME 1 , ISSUE 1 ( January-June, 2017 ) > List of Articles


Pharmacovigilance in India and its Impact in Patient Management

Geeta Sharma, Rahat Kumar, Jaswinder Singh, Vikram Bhandari, Narinder Singh

Citation Information : Sharma G, Kumar R, Singh J, Bhandari V, Singh N. Pharmacovigilance in India and its Impact in Patient Management. Curr Trends Diagn Treat 2017; 1 (1):27-33.

DOI: 10.5005/jp-journals-10055-0006

License: NA

Published Online: 01-06-2017

Copyright Statement:  NA


How to cite this article

Sharma G, Kumar R, Singh J, Bhandari V, Singh N. Pharmacovigilance in India and its Impact in Patient Management. Curr Trends Diagn Treat 2017;1(1):27-33.

  1. The importance of pharmacovigilance – safety monitoring of medicinal products [Internet]. Geneva: World Health Organization; 2002 [cited 2016 Sep 21]. Available from:
  2. World Health Organization. [cited 2016 Sep 21]. Available from:
  3. History [Internet]. Silver Spring: US Food and Drug Administration; 2013 [cited 2016 Sep 21]. Available from:
  4. Wikipedia, The Free Encyclopedia; 2012 Jun, at 15:27 UTC [cited 2016 Sep 21]. Available from:;
  5. The thalidomide disaster, lessons from the past. Methods Mol Biol 2013;947:575-586.
  6. U.S. Food and Drug Administration. [cited 2016 Sep 21]. Available from:
  7. Past, present and future of pharmacovigilance in India. Syst Rev Pharm 2011 Jan;2(1):55-58.
  8. European Medicines Agency. [cited 2016 Sep 21]. Available at:
  9. Version 1.0 Published by Indian Pharmacopoeia Commission. National Coordination Centre – Pharmacovigilance Programme of India, Ministry of Health & Family Welfare, Government of India. Printed by Nutech Photolithographers, B-240, Okhla Industrial Area, Phase-I, New Delhi.
  10. Reporting systems for rare side effects of non-narcotic analgesics in India. Problems and opportunities. Med Toxicol 1986;1(1 Suppl 1):110-113.
  11. CDSCO, Ministry of Health and Family Welfare, Government of India; 2004 Nov [cited 2015 May 25]. Available from:
  12. Adverse drug reaction monitoring in India. J Assoc Physicians India 1993 Jun;41(6):374-376.
  13. Role of pharmacovigilance in India: an overview. Online J Public Health Inform 2015 Jul;7(2):e223.
  14. National pharmacovigilance program. Indian Pediatr 2006 Jan;43(1):27-32.
  15. Benefit-risk balance for marketed drugs: evaluating safety signals – report of CIOMS working group IV. Geneva: CIOMS; 1998 [cited 2016 Sep 21]. Available from:
  16. Clioquinol-subacutemyelo-opticoneuropathy (SMON) in Indians. Some observations on SMON from Bombay. J Neurol Neurosurg Psychiatry 1977;40(3):268-275.
  17. Phenylpropanolamine-induced intraventricular hemorrhage. Neurol India 2003 Mar;51(1):117-118.
  18. [cited 2016 Sep 21]. Available from:
  19. WHO Library Cataloguing-in-Publication Data 2006. [cited 2016 Sep 21]. Available from:
  20. 009 [Internet]; 2004 Oct [cited 2016 Sep 21];6. Available from:
  21. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999;77(10):801-807.
  22. Geneva: World Health Organization; 2004 [cited 2016 Sep 21]. Available from:
  23. Drug utilisation patterns in the Third World. Pharmacoeconomics 1996 Apr;9(4):286-294.
  24. Changing prescribing in the light of tolerability concerns: how is this best achieved? Drug Saf 1999 Sep;21(3):153-160.
  25. The selection of essential drugs. Technical report series 615. Geneva: World Health Organization; 1977.
  26. Drug utilization studies – an overview. Int J Pharm Sci Nanotechnol 2010 Apr;3(1):803-810.
  27. Multidisciplinary team care for CKD-MBD. Achieving KDIGO guideline recommendations in the bundling era. Nephrol News Issues 2014 Apr;28(4):24-26.
  28. [Risk of hypercalcemia and hipervitaminosis D induced by calcifediol. Review of cases reported to the Spanish Pharmacovigilance System]. Med Clin (Barc). 2013 Jul;141(2):88-89.
  29. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990 Dec;336(8727):1360-1362.
  30. French Association of Regional Pharmacovigilance Centers. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study. Pharmacoepidemiol Drug Saf 2012 Mar;21(3):314-319.
  31. ASN Chronic Kidney Disease Advisory Group. Finding a common language for patient safety in CKD. Clin J Am Soc Nephrol 2012 Apr;7(4):689-695.
  32. European Medicines Agency recommends action plan to deal with possible presence of endotoxins in Baxter peritoneal dialysis solutions [Internet]. [cited 2016 Sep]. Available from:
  33. com. Extraneal company core data sheet. Deerfield (IL): Baxter Healthcare Corporation; 2007 [cited 2016 Sep 21]. Available from:
  34. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf 2013 Apr;5:105-112.
  35. Significant hypoglycemia secondary to icodextrin peritoneal dialysate in a diabetic patient. Anesth Analg 2007 Jun;104(6):14731474.
  36. Spontaneous tendon ruptures in patients with end-stage renal disease. Kidney Blood Press Res 2009;32(1):32-36.
  37. Newly licensed drugs. BMJ 1996 Nov;313(7066):1157-1158.
  38. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002 Aug;36(2):451-455.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.